Carpenter, R. L., Paw, I, Dewhirst, M. W., Lo, H.-W. Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Oncogene, Published ahead of print, Jan 27, 2014. PMC4112182, 2014
Carpenter, R. L. and Lo, H.-W. STAT3-regulated Genes Relevant to Human Cancers. In Special Issue: STAT3 Signalling in Cancer: Friend or Foe. Cancers 6:897-925, 2014.
Zhu, H., Carpenter, R. L, Han, W., and Lo, H.-W. The GLI1 splice variant TGLI1 is a novel mediator of glioblastoma angiogenesis and growth. Cancer Letters 343(1):51-61. 2014.
Han, W., Carpenter, R. L., Cao, X. and Lo, H.-W. STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. Molecular Carcinogenesis 52(12):959-969, 2013
Carpenter, R. L, Han, W., Paw, I. and Lo, H.-W. HER2 phosphorylates and destabilizes proapoptotic PUMA, leading to antagonized apoptosis in cancer cells. PLoS ONE 8(11):e78836, 2013.
Lo, H.-W. Akt destabilizes p57Kip2: Akt at the converging crossroad? (Invited News & Views) Cell Cycle 12(6):870-871, 2013.
Han, W., Carpenter, RL, and Lo, H.-W. TGLI1 upregulates expression of VEGFR2 and VEGF-A, leading to a robust VEGF-VEGFR2 autocrine loop and cancer cell growth. doi:10.1166/ch.2013.1006. Cancer Hallmarks 1: 28-37, 2013.
Carpenter, R. L and Lo, H.-W. Regulation of Apoptosis by HER2 in Breast Cancer. Journal of Carcinogenesis & Mutagenesis S7:300, 2013.
Cao, X., Geradts, J., Dewhirst, M. and Lo, H.-W. Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene 31:104-115, 2012.
Carpenter, RL. and Lo, H.-W. Hedgehog Pathway and GLI1 Isoforms in Human Cancer. (invited review) Discovery Medicine 13:105-113, 2012.
Han, W. and Lo, H.-W. Landscape of EGFR Signaling Network in Human Cancers: Biology and Therapeutic Response in Relation to Receptor Subcellular Locations. (invited review) Cancer Letters 318:124-134, 2012.
Huang, X., Yuan, F., Liang, M., Lo*, H.-W. (co-corresponding author), Shinohara*, M. L., Robertson, C., Zhong*, P. M-HIFU inhibits tumor growth via suppressing STAT3 activity and enhancing tumor specific immunity in a transplant tumor model of prostate cancer. PLoS ONE 7: e41632, 2012. *Co-corresponding Authors
Carpenter, R. L. and Lo, H.-W. Identification, Functional Characterization and Pathobiological Significance of GLI1 Isoforms in Human Cancers. In Vitamins & Hormones-HEDGEHOG SIGNALING. Ed: Gerald Litwack. Elsevier Inc., Volume 88, pp. 115-140, 2012.
Carpenter, RL. and Lo, H.-W. Dacomitinib, an Emerging HER-Targeted Therapy for Non-Small Cell Lung Cancer. Journal of Thoracic Disease, 4:639-642, 2012.
Lo, H.-W. EGFR-targeted Cancer Therapy: Promise, Problems and Potential Solutions. Translational Medicine 1:105e. doi:10.4172/2161-1025.1000105e, 2011.
Cao, X., Zhu, H., Ali-Osman, F. and Lo, H.-W. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A novel mechanism of EGFR-driven antagonism of apoptosis. Molecular Cancer 10:26, 2011.
Zhong, P., Xing, F., Huang, X., Zhu, H., Lo, H.-W., Zhong, X., Pruitt, S. and Robertson, C. HIFU as a Neoadjuvant Therapy in Cancer Treatment. 10TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND (ISTU 2010) 1359:289-294, 2011.
Lo, H.-W. EGFR-targeted therapy in malignant glioma: Novel aspects and mechanisms of drug resistance. (invited review) Current Molecular Pharmacology 3:37-52, 2010.
Lo, H.-W. (corresponding author), et al. COX-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. (Selected as Journal Highlight; the most cited article published in 2010 in Molecular Cancer Research) Molecular Cancer Research 8:232-245, 2010.
Zhu, H., Cao, X., Ali-Osman, F., Keir, S. and Lo, H.-W. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Letters 294:101-110, 2010.
Zhu, H. and Lo, H.-W. The human glioma-associated oncogene Homolog 1 (GLI1) family of transcription factors in gene regulation and diseases. (invited review) Current Genomics 11:238-245, 2010.
Lo, H.-W. Nuclear Mode of the EGFR Signaling Network: Biology, Prognostic Value, and Therapeutic Implications. (invited review) Discovery Medicine 10:44-51, 2010.
Lo, H.-W. Emerging therapeutic targets and agents for glioblastoma therapy. (invited editorial) Anti-Cancer Agents in Medicinal Chemistry Part I. 10(6):437, 2010 and Part II. 10(7):511. 2010.
Lo, H.-W. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. (invited review) Current Cancer Drug Targets 10:840-848, 2010.
Lo, H.-W. (corresponding author), et al. A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. Cancer Research 17:6790-6798, 2009.
Lo, H.-W. (corresponding author), et al. Constitutively activated STAT3 frequently co-expresses with EGFR in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clinical Cancer Research 14:6042-6054, 2008.
Lo, H.-W., Hsu, S-C., Xia, W., Cao, X., Shih, J.-Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N. and Hung, M.-C. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Research 67:9066-9076, 2007.
Hanada, N., Lo, H.-W. (co-first author), Day, C.-P., Pan, Y., Nakajima, Y. and Hung, M-C. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Molecular Carcinogenesis 45:10-17, 2006.
Lo, H.-W. and Hung, M.-C. Nuclear EGFR signaling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. British Journal of Cancer 94:184-188, 2006.
Lo, H.-W., Ali-Seyed M., Wu, Y., Bartholomeusz, G., Hsu, Sheng-Chieh, and Hung, M.-C. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin b1 and CRM1. Journal of Cellular Biochemistry 98:1570-1583, 2006.
Lo, H.-W., Hsu, S.-C., and Hung, M.-C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Research and Treatment 95:211-218, 2006.
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M. Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y. and Hung, M.-C. Nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway. Cancer Cell 6:575-589, 2005.
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F. and Hung, M.-C. Novel prognostic value of nuclear EGF receptor in breast cancer. Cancer Research 65:338-348, 2005.
Lo, H.-W., Day, C.-P., Hung, M.-C. Cancer-specific Gene Therapy. Advances in Genetics 54:235-255, 2005.Wang, S-C., Lien, H-C., Xia, W., Chen, I-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Bartholomeusz, G., Ou-Yang, F., Giri, D.K. and Hung, M.-C. Binding at and transactivation of COX-2 promoter by nuclear tyrosine kinase receptor ErbB2. Cancer Cell 6:251-261, 2004.